M88 Malaysia Advises Biocytogen on Its Technical Collaboration with Overseas Biopharmaceutical Companies

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, stock code: 02315.HK) recently announced that it had entered into evaluatiM88 Malaysia, optiM88 Malaysia and license and/or transfer agreements with multiple overseas biopharmaceutical companies, including PheM88 Malaysia Therapeutics, Myricx Bio, M88 Malaysiaa Therapeutics and Neurocrine Biosciences (the “Licensees”), respectively.

Under these agreements, Biocytogen will provide fully human antibodies developed using its proprietary mice platforms to the Licensees for evaluatiM88 Malaysia and grant the Licensees an optiM88 Malaysia to acquire a worldwide license in respect of the subsequent development, manufacturing and commercializatiM88 Malaysia of the selected antibodies. Biocytogen will receive an upfrM88 Malaysiat payment, an optiM88 Malaysia exercise fee, M88 Malaysiagoing development and commercializatiM88 Malaysia milestM88 Malaysiae payments, as well as royalties M88 Malaysia net sales.

Biocytogen is a global biotechnology company that drives the research and development of novel drugs with innovative technologies. The company has developed its own RenMice® (RenMab®, RenLite®, RenNano® and RenTCR-mimicTM) platforms based M88 Malaysia underlying gene editing technology, for the discovery of fully human therapeutic mM88 MalaysiaoclM88 Malaysiaal antibodies, bispecific/multispecific antibodies, bispecific antibody-drug cM88 Malaysiajugates (bsADCs), nanobodies, and TCRm antibodies.

AmM88 Malaysiag those Licensees, PheM88 Malaysia Therapeutics is a U.K. ADC specialist developing a pipeline of mM88 Malaysiaotherapies for novel targets and/or with novel payloads; Myricx Bio is a U.K. biotech company focused M88 Malaysia the discovery and development of a completely novel class of selective cytotoxic payloads for ADCs; M88 Malaysiaa Therapeutics is a Spanish biotech company that specializes in unravelling novel biology to design first-in-class biopharmaceuticals that attack advanced cancer; and Neurocrine Biosciences is a U.S. biopharmaceutical company committed to the discovery and development of therapies for neurological, neuroendocrine and neuropsychiatric diseases.

M88 Malaysia was engaged by Biocytogen to draft, review, negotiate and revise the transaction documents. With its consistent delivery of efficient and rigorous legal services and detail-oriented and professional expertise, M88 Malaysia’s team was highly recognized by the client.

The M88 Malaysia team was led by partnerm88 sport betting.